Literature DB >> 12010985

Induction of interleukin-12 and gamma interferon requires tumor necrosis factor alpha for protective T1-cell-mediated immunity to pulmonary Cryptococcus neoformans infection.

Amy C Herring1, John Lee, Roderick A McDonald, Galen B Toews, Gary B Huffnagle.   

Abstract

The development of T1-cell-mediated immunity is required to clear a pulmonary Cryptococcus neoformans infection. The objective of these studies was to determine the mechanism by which tumor necrosis factor alpha (TNF-alpha) augments the development of pulmonary T1 immunity to C. neoformans infection. TNF-alpha expression was detected in lavage sample cells at days 2, 3, and 7 following C. neoformans infection. The numbers of CFU in the lung were not different between control and anti-TNF-alpha-treated mice at any time point examined during the afferent phase of the response (days 0 to 7). However, neutralization of TNF-alpha prevented the initiation of pulmonary clearance during the efferent phase of the response (day 14). Administration of anti-TNF-alpha monoclonal antibody (day 0) diminished the lung levels of TNF-alpha, interleukin-12 (IL-12), and gamma interferon (IFN-gamma) induced by C. neoformans at day 7 postinfection. Neutralization of TNF-alpha (day 0) also altered the IFN-gamma/IL-4 ratio in the lung-associated lymph nodes at day 7 following C. neoformans infection. Anti-TNF-alpha-treated mice developed a pulmonary eosinophilia at day 14 postinfection. Consistent with the pulmonary eosinophilia, anti-TNF-alpha-treated mice exhibited elevated serum immunoglobulin E and inhibition of the anticryptococcal delayed-type hypersensitivity response, indicating a shift toward a T2 response. Neutralization of IL-12 also prevented lung leukocyte production of IFN-gamma in response to the infection. These findings demonstrate that afferent-phase TNF-alpha production is essential for the induction of IL-12 and IFN-gamma and neutralization of early TNF-alpha results in a T2 shift of the T1/T2 balance of antifungal immunity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12010985      PMCID: PMC127967          DOI: 10.1128/IAI.70.6.2959-2964.2002

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  38 in total

1.  Purified capsular polysaccharide of Cryptococcus neoformans induces interleukin-10 secretion by human monocytes.

Authors:  A Vecchiarelli; C Retini; C Monari; C Tascini; F Bistoni; T R Kozel
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

2.  Afferent phase production of TNF-alpha is required for the development of protective T cell immunity to Cryptococcus neoformans.

Authors:  G B Huffnagle; G B Toews; M D Burdick; M B Boyd; K S McAllister; R A McDonald; S L Kunkel; R M Strieter
Journal:  J Immunol       Date:  1996-11-15       Impact factor: 5.422

3.  Direct interactions of human natural killer cells with Cryptococcus neoformans inhibit granulocyte-macrophage colony-stimulating factor and tumor necrosis factor alpha production.

Authors:  J W Murphy; A Zhou; S C Wong
Journal:  Infect Immun       Date:  1997-11       Impact factor: 3.441

4.  Contribution of tumour necrosis factor-alpha (TNF-alpha) in host defence mechanism against Cryptococcus neoformans.

Authors:  K Kawakami; X Qifeng; M Tohyama; M H Qureshi; A Saito
Journal:  Clin Exp Immunol       Date:  1996-12       Impact factor: 4.330

5.  Cryptococcus neoformans and cryptococcal glucuronoxylomannan, galactoxylomannan, and mannoprotein induce different levels of tumor necrosis factor alpha in human peripheral blood mononuclear cells.

Authors:  W Chaka; A F Verheul; V V Vaishnav; R Cherniak; J Scharringa; J Verhoef; H Snippe; I M Hoepelman
Journal:  Infect Immun       Date:  1997-01       Impact factor: 3.441

6.  T cells cooperate with passive antibody to modify Cryptococcus neoformans infection in mice.

Authors:  R R Yuan; A Casadevall; J Oh; M D Scharff
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-18       Impact factor: 11.205

7.  Tumor necrosis factor-inducing activities of Cryptococcus neoformans components.

Authors:  D Delfino; L Cianci; M Migliardo; G Mancuso; V Cusumano; C Corradini; G Teti
Journal:  Infect Immun       Date:  1996-12       Impact factor: 3.441

8.  Expression of cytokines and inducible nitric oxide synthase mRNA in the lungs of mice infected with Cryptococcus neoformans: effects of interleukin-12.

Authors:  K Kawakami; M Tohyama; X Qifeng; A Saito
Journal:  Infect Immun       Date:  1997-04       Impact factor: 3.441

9.  Effects of interleukin-10 on human peripheral blood mononuclear cell responses to Cryptococcus neoformans, Candida albicans, and lipopolysaccharide.

Authors:  S M Levitz; A Tabuni; S H Nong; D T Golenbock
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

10.  In vivo depletion of murine CD8 positive T cells impairs survival during infection with a highly virulent strain of Cryptococcus neoformans.

Authors:  C H Mody; G H Chen; C Jackson; J L Curtis; G B Toews
Journal:  Mycopathologia       Date:  1994-01       Impact factor: 2.574

View more
  58 in total

Review 1.  Induction of protective immunity against cryptococcosis.

Authors:  Karen L Wozniak; Sarah Hardison; Michal Olszewski; Floyd L Wormley
Journal:  Mycopathologia       Date:  2011-12-06       Impact factor: 2.574

2.  Responses to Leishmania donovani in mice deficient in interleukin-12 (IL-12), IL-12/IL-23, or IL-18.

Authors:  Henry W Murray; Christine W Tsai; Jianguo Liu; Xiaojing Ma
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

3.  Transient neutralization of tumor necrosis factor alpha can produce a chronic fungal infection in an immunocompetent host: potential role of immature dendritic cells.

Authors:  Amy C Herring; Nicole R Falkowski; Gwo-Hsiao Chen; Rod A McDonald; Galen B Toews; Gary B Huffnagle
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

Review 4.  Immune response and immunotherapy to Cryptococcus infections.

Authors:  Qing Zhou; William J Murphy
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

5.  Neutralization of tumor necrosis factor alpha suppresses antigen-specific type 1 cytokine responses and reverses the inhibition of mycobacterial survival in cocultures of immune guinea pig T lymphocytes and infected macrophages.

Authors:  Hyosun Cho; David N McMurray
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

6.  Cryptococcus gattii infection dampens Th1 and Th17 responses by attenuating dendritic cell function and pulmonary chemokine expression in the immunocompetent hosts.

Authors:  Pornpimon Angkasekwinai; Nuntarat Sringkarin; Oratai Supasorn; Madtika Fungkrajai; Yui-Hsi Wang; Methee Chayakulkeeree; Popchai Ngamskulrungroj; Nasikarn Angkasekwinai; Kovit Pattanapanyasat
Journal:  Infect Immun       Date:  2014-06-30       Impact factor: 3.441

7.  CCR2 mediates conventional dendritic cell recruitment and the formation of bronchovascular mononuclear cell infiltrates in the lungs of mice infected with Cryptococcus neoformans.

Authors:  John J Osterholzer; Jeffrey L Curtis; Timothy Polak; Theresa Ames; Gwo-Hsiao Chen; Rod McDonald; Gary B Huffnagle; Galen B Toews
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

8.  Improved survival of mice deficient in secretory immunoglobulin M following systemic infection with Cryptococcus neoformans.

Authors:  Krishanthi S Subramaniam; Kausik Datta; Matthew S Marks; Liise-Anne Pirofski
Journal:  Infect Immun       Date:  2009-11-09       Impact factor: 3.441

9.  Induction of T helper type 1 responses by a polysaccharide deacetylase from Cryptococcus neoformans.

Authors:  Carmelo Biondo; Concetta Beninati; Mauro Bombaci; Luciano Messina; Giuseppe Mancuso; Angelina Midiri; Roberta Galbo; Giuseppe Teti
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

10.  Invasive Cryptococcosis and adalimumab treatment.

Authors:  Juan P Horcajada; Jose L Peña; Víctor M Martínez-Taboada; Trinitario Pina; Isabel Belaustegui; María Eliecer Cano; Daniel García-Palomo; M Carmen Fariñas
Journal:  Emerg Infect Dis       Date:  2007-06       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.